A detailed history of Engineers Gate Manager LP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 67,625 shares of APLS stock, worth $2.26 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
67,625
Previous 12,169 455.72%
Holding current value
$2.26 Million
Previous $466,000 318.45%
% of portfolio
0.04%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$28.84 - $41.15 $1.6 Million - $2.28 Million
55,456 Added 455.72%
67,625 $1.95 Million
Q2 2024

Aug 14, 2024

BUY
$38.07 - $59.71 $232,988 - $365,425
6,120 Added 101.17%
12,169 $466,000
Q1 2024

May 15, 2024

BUY
$55.39 - $72.47 $123,021 - $160,955
2,221 Added 58.02%
6,049 $355,000
Q4 2023

Feb 14, 2024

SELL
$37.14 - $64.82 $836,875 - $1.46 Million
-22,533 Reduced 85.48%
3,828 $229,000
Q3 2023

Nov 14, 2023

BUY
$23.65 - $89.22 $540,307 - $2.04 Million
22,846 Added 649.96%
26,361 $1 Million
Q2 2023

Aug 14, 2023

BUY
$76.68 - $93.31 $269,530 - $327,984
3,515 New
3,515 $320,000
Q2 2022

Aug 15, 2022

SELL
$35.07 - $59.21 $374,477 - $632,244
-10,678 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$35.46 - $54.12 $378,641 - $577,893
10,678 New
10,678 $543,000
Q2 2021

Aug 16, 2021

SELL
$40.9 - $64.9 $307,977 - $488,697
-7,530 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$40.8 - $57.39 $71,808 - $101,006
-1,760 Reduced 18.95%
7,530 $323,000
Q4 2020

Feb 16, 2021

BUY
$30.79 - $57.2 $286,039 - $531,388
9,290 New
9,290 $531,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.68B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.